Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
Natalin and Acelagraftare the latest additions to Celularity’s portfolio of HCT/P 361products for use in the treatment of partial and full thickness acute and chronic wounds. Natalin is a decellularized dehydrated amnion derived tri-layer graft and Acelagraft is a decellularized dehydrated amnion derived bi-layer graft. Both Natalin and Acelagraft are indicated for use in partial and full thickness acute and chronic wounds.“We are extremely pleased to receive these TRG recommendation letters on important additions to our portfolio of human placental-derived biomaterials, which serves as a further testament to our commitment to innovate in the wound care sector and will further enable us to build on our commercial momentum,” commented Dr. Robert Hariri, Chairman and CEO of Celularity.